Ken Griffin I Teos Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$10.33 - $18.09 $279,943 - $490,239	27,100 Added 84.16%	59,300 $880,000
Q1 2024 May 15, 2024	SELL	$9.89 - $13.64 $255,162 - $351,912	-25,800 Reduced 44.48%	32,200 $439,000
Q4 2023 Feb 14, 2024	BUY	$8.57 - $11.06 $265,670 - $342,860	31,000 Added 114.81%	58,000 $635,000
Q3 2023 Nov 14, 2023	BUY	$10.95 - $14.6 $97,455 - $129,940	8,900 Added 49.17%	27,000 $295,000
Q2 2023 Aug 14, 2023	BUY	$12.93 - $18.05 $42,669 - $59,565	3,300 Added 22.3%	18,100 $239,000
Q1 2023 May 15, 2023	BUY	$13.02 - $22.62 $19,530 - $33,930	1,500 Added 11.28%	14,800 $201,000
Q4 2022 Feb 14, 2023	BUY	$17.77 - $21.6 $236,341 - $287,280	13,300 New	13,300 $259,000

151

36.4M

653K

1.48M

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $330M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.